How to Read Your Blood Work Results Like a Pro

Why Blood Work Is the Foundation of Safe Testosterone Therapy

Lab results are not just paperwork your clinic collects before renewing a prescription. They are the single most reliable early-warning system for both under-treatment and over-treatment. A man can feel great while his hematocrit quietly climbs past 54%, or feel terrible while his total testosterone reads 700 ng/dL because his SHBG is sky-high and his free testosterone is functionally low.

Reading your own results is not about replacing your physician. It is about showing up to your follow-up appointment as an informed participant rather than a passive recipient.

The Difference Between Reference Range and Optimal Range

Every lab prints a reference range, which is the statistical middle 95% of a population sample. That population usually includes sedentary men, men with undiagnosed hypogonadism, and men across a wide age span. A 72-year-old's "normal" 280 ng/dL total testosterone is mathematically inside many reference ranges but is not a therapeutic target for a 35-year-old man on TRT.

The Endocrine Society's 2018 Clinical Practice Guideline for testosterone therapy recommends targeting the mid-normal range for young healthy men, roughly 400 to 700 ng/dL total testosterone, rather than simply clearing the lower threshold of 300 ng/dL [1].

Timing Your Draw Correctly

Draw timing changes results dramatically. For men injecting testosterone cypionate or enanthate, a trough draw (24 to 48 hours before the next injection) reflects your lowest circulating level. A peak draw (48 to 72 hours post-injection) reflects your highest. Neither is intrinsically "correct," but consistency matters. Always draw at the same point in your injection cycle so results are comparable across visits.

Men on daily subcutaneous testosterone or transdermal gel should draw at the same time of day, ideally in the morning, because diurnal variation in testosterone secretion still affects readings even on exogenous therapy [2].

Total Testosterone: The Most Overrated Single Number

Total testosterone measures both the fraction bound to SHBG (unavailable to tissues) and the fraction bound loosely to albumin plus free (bioavailable). A total of 600 ng/dL sounds great on paper. It may not be if SHBG is 70 nmol/L.

What the Number Actually Tells You

Total testosterone is a useful screening value and a necessary baseline. The Endocrine Society defines biochemical hypogonadism as a total testosterone consistently below 300 ng/dL on two morning draws, confirmed at least four weeks apart [1]. That 300 ng/dL threshold triggers diagnostic evaluation, not automatic treatment.

When Total T Misleads You

High SHBG (seen in hyperthyroidism, liver disease, aging, and some genetic variants) binds more testosterone, lowering the bioavailable fraction even when total T looks healthy. Obesity and insulin resistance lower SHBG, doing the opposite: total T appears low while free T is proportionally higher.

A 2013 analysis published in the Journal of Clinical Endocrinology and Metabolism (N=480) found that SHBG-adjusted free testosterone correlated significantly better with symptoms of hypogonadism than total testosterone alone [3].

Free Testosterone: The Number That Actually Matters to Your Cells

Free testosterone is the fraction not bound to any protein. It represents roughly 1 to 3% of total testosterone. Direct immunoassay measurements of free T are notoriously inaccurate at low concentrations. Most academic endocrinology labs prefer the calculated free testosterone using the Vermeulen equation, which requires total testosterone, SHBG, and albumin [4].

Reference Ranges and Therapeutic Targets

The typical adult male free testosterone range by the Vermeulen calculation is 50 to 224 pg/mL, though some labs report in nmol/L. Men on TRT often target the upper half of this range (approximately 150 to 224 pg/mL), especially if they remain symptomatic at mid-range totals.

Why the Assay Method Matters

Ask your lab which free testosterone method they use. Equilibrium dialysis is the gold standard. Direct analog immunoassay, which many commercial labs still use, can read 20 to 30% lower than dialysis in the same blood sample [4]. If your result seems inconsistent with your symptoms, request the calculated or dialysis-based value specifically.

Estradiol (E2): The Most Misunderstood Marker on a TRT Panel

Testosterone aromatizes to estradiol. On TRT, some rise in estradiol is expected and physiologically appropriate. Estrogen in men protects bone density, supports libido, and maintains cardiovascular health. The reflex prescription of anastrozole for any estradiol above 35 pg/mL is not supported by current evidence.

Sensitive vs. Standard Assay

Order the sensitive estradiol assay (LC-MS/MS), not the standard immunoassay. The standard assay cross-reacts with other steroids and reliably overestimates estradiol in men, sometimes by 15 to 20 pg/mL [5]. Most men on TRT with estradiol readings above 60 pg/mL on a standard assay are actually in the 40 to 50 pg/mL range on LC-MS/MS.

Clinical Thresholds

A 2021 review in the Journal of Clinical Endocrinology and Metabolism concluded that men with estradiol below 10 pg/mL experienced increased bone resorption markers, decreased libido, and worsened mood, and that symptoms of estrogen excess (gynecomastia, water retention, mood lability) became clinically relevant above approximately 60 pg/mL on the sensitive assay [5].

If your sensitive E2 is between 20 to 55 pg/mL and you are asymptomatic, an aromatase inhibitor is unlikely to improve your quality of life and may worsen bone density and lipids.

Hematocrit and Hemoglobin: The Safety Markers Most Men Ignore

Testosterone stimulates erythropoiesis. Hematocrit (the percentage of red blood cells in whole blood) rises predictably on TRT, usually within the first 3 to 6 months. This is the most common dose-limiting adverse effect of testosterone therapy.

The 54% Ceiling

The Endocrine Society 2018 guideline states: "We suggest checking hematocrit at baseline, at 3 to 6 months, and then annually. We suggest withholding testosterone therapy if the hematocrit is greater than 54%" [1]. That 54% number is not arbitrary. Above that threshold, blood viscosity increases in a pattern associated with elevated thrombotic risk.

What to Do If Your Hematocrit Is Elevated

A hematocrit between 50 to 54% warrants a conversation with your clinician, not panic. Options include reducing the testosterone dose, switching from weekly injections to more frequent smaller injections (which blunts the peak-trough swing), or in some cases a therapeutic phlebotomy to bring hematocrit below 50%.

A single CBC reading of 52% in a dehydrated patient means less than a pattern of 51%, 52%, 53% over three consecutive draws.

SHBG: The Protein That Controls How Much Testosterone You Actually Use

Sex hormone-binding globulin is produced by the liver and binds testosterone with high affinity. High SHBG means less free testosterone is available to tissues even when total testosterone is adequate. Low SHBG means more free testosterone is available, but the molecule is also cleared faster, which is why men with low SHBG often do better on daily or every-other-day testosterone protocols rather than weekly injections.

Normal Range and Clinical Interpretation

The adult male reference range for SHBG is approximately 10 to 57 nmol/L. Values below 20 nmol/L are considered low. Values above 50 nmol/L significantly reduce the bioavailable fraction of total testosterone.

Lifestyle factors that lower SHBG include obesity, insulin resistance, hypothyroidism, and exogenous anabolic steroid use. Factors that raise SHBG include aging, hyperthyroidism, liver disease, high estrogen, and some anticonvulsants [6].

LH and FSH: What They Tell You About Your Own Production

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are pituitary signals. LH drives testicular testosterone production; FSH drives spermatogenesis.

On Exogenous Testosterone

Once you begin exogenous testosterone, the hypothalamic-pituitary axis receives a negative feedback signal and suppresses LH and FSH output. LH may fall to <0.1 mIU/mL and FSH to near zero within weeks. This is expected. It is not a sign of pituitary pathology; it is the normal physiologic response to exogenous androgen [7].

Why You Still Want to Know Your Baseline

If your pre-treatment LH and FSH were both low (secondary hypogonadism), your clinician may evaluate for a pituitary adenoma or hemochromatosis. If both were high before treatment (primary hypogonadism), your testes are the limiting factor, not your pituitary. These distinctions affect whether you might be a candidate for hCG co-therapy to preserve testicular function and fertility.

PSA: The Cancer Screening Marker That Requires Context

Prostate-specific antigen (PSA) is produced by prostate cells. Testosterone therapy does not cause prostate cancer, but it may accelerate growth of a pre-existing tumor. This is why PSA screening before and during TRT is standard practice.

Baseline and Monitoring Thresholds

The Endocrine Society 2018 guideline recommends PSA at baseline and at 3 to 6 months, then per age-appropriate screening guidelines [1]. A PSA rise of more than 1.4 ng/mL in any 12-month period on TRT, or an absolute PSA above 4.0 ng/mL, warrants urologic referral. Men with a first-degree family history of prostate cancer or of African descent should be referred at PSA above 3.0 ng/mL [1].

PSA Velocity vs. Single Reading

A PSA of 3.2 ng/mL that has been stable for three years in a 58-year-old man is very different from a PSA of 3.2 ng/mL that was 1.8 ng/mL four months ago. Velocity, not just absolute value, is the clinically meaningful metric.

Complete Metabolic Panel (CMP): Liver and Kidney Health on TRT

The CMP includes 14 analytes covering kidney function (creatinine, BUN, eGFR), liver function (ALT, AST, alkaline phosphatase, bilirubin), electrolytes, and glucose.

Liver Markers

Oral 17-alpha-alkylated androgens (no longer used in legitimate TRT) caused significant hepatotoxicity. Injectable testosterone cypionate, enanthate, and topical gels do not produce meaningful liver enzyme elevations in standard doses. Mild ALT or AST elevation on TRT is more likely explained by muscle breakdown from resistance training than liver injury. Creatine kinase (CK) can also help differentiate [8].

Kidney Function

EGFR below 60 mL/min/1.73m2 (CKD stage 3) warrants extra caution with TRT because testosterone may worsen erythrocytosis-related blood viscosity in men with impaired renal clearance. Report any downward eGFR trend to your clinician even if you remain above 60.

Glucose and A1c

Testosterone therapy modestly improves insulin sensitivity in hypogonadal men with type 2 diabetes. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found no significant increase in cardiovascular events with testosterone therapy in men with hypogonadism and elevated cardiovascular risk, and also found improvements in glycemic control in a pre-specified subgroup analysis [9].

A fasting glucose above 100 mg/dL at baseline or an A1c above 5.7% should prompt lifestyle counseling and repeat monitoring at 3 months.

Lipid Panel: Reading Your Cardiovascular Risk Correctly

A standard lipid panel reports total cholesterol, LDL, HDL, triglycerides, and sometimes VLDL and non-HDL cholesterol.

How Testosterone Affects Lipids

Testosterone therapy modestly lowers HDL (the "good" cholesterol) by approximately 5 to 7% in most studies. The TRAVERSE trial found no significant difference in major adverse cardiovascular events (MACE) at a median follow-up of 33 months, though a pre-specified analysis showed a higher rate of non-fatal atrial fibrillation and pulmonary embolism in the testosterone group [9]. These findings reinforce the need for lipid and cardiovascular monitoring, not the abandonment of TRT in appropriate candidates.

LDL Targets Are Risk-Stratified

There is no single LDL target for all men. The American College of Cardiology 2019 guidelines stratify LDL targets by 10-year ASCVD risk. Men with established cardiovascular disease target LDL below 70 mg/dL. Men at low risk may tolerate LDL up to 130 mg/dL without pharmacologic intervention [10].

Know your 10-year ASCVD risk score (calculable at the ACC/AHA online tool) before interpreting your LDL in isolation.

A Practical Framework for Reading Your Own Panel

When your lab results arrive, work through them in this order rather than fixating on a single number:

1. Safety markers first. Check hematocrit, PSA, and eGFR before anything else. These are the markers where out-of-range values require prompt action, not a "let's see at the next visit" approach.

2. Hormone axis second. Review total testosterone, free testosterone (calculated), estradiol (sensitive), SHBG, LH, and FSH together as a system. No single number tells the full story.

3. Metabolic health third. Scan fasting glucose, A1c, liver enzymes, and the full lipid panel. Testosterone therapy exists within the context of your overall cardiometabolic health, and ignoring that context is how side effects accumulate unnoticed.

4. Compare to your own prior results, not just the reference range. A trend matters more than a single snapshot. A hematocrit moving from 44% to 47% to 51% over three draws tells a different story than a stable 51% for two years.

5. Write your questions before the appointment. Arrive with three specific questions based on values that changed more than 10% between draws or that sit in the upper or lower 10% of the reference range.

Interpreting Results When You Are Not on TRT Yet

If you are in the evaluation phase, your lab draw should include at minimum: two morning total testosterone draws at least four weeks apart, LH, FSH, SHBG, prolactin, CBC, CMP, fasting lipids, and PSA (if over 40). The Endocrine Society recommends confirming hypogonadism with two separate morning draws before initiating therapy [1].

Prolactin is not on every standard panel but matters: a prolactin above 20 ng/mL in a man with low testosterone should prompt MRI of the pituitary to rule out a prolactinoma before starting TRT, because treating prolactin excess (usually with cabergoline 0.25 to 0.5 mg twice weekly) may restore natural testosterone without exogenous therapy [7].

Common Mistakes Men Make When Reviewing Lab Results

Focusing only on total testosterone is the single most common error. A close second is using the wrong estradiol assay. A third is drawing blood at inconsistent points in the injection cycle and comparing results across different timing windows as if they reflect the same physiologic state.

Men also frequently apply bodybuilder-forum reference ranges rather than clinical guideline thresholds. Online communities often cite hematocrit ceilings of 56 to 58% as acceptable. The Endocrine Society and most academic endocrinology programs set a hard ceiling of 54% for a reason backed by hemorheology data [1].

Finally: a lab result printed outside the reference range is not automatically dangerous, and a result printed inside the reference range is not automatically fine. Context, trend, and symptoms interpreted together produce clinical meaning. No single number does.